about
Correlation between compartmental tenofovir concentrations and an ex vivo rectal biopsy model of tissue infectibility in the RMP-02/MTN-006 phase 1 studyMucosal effects of tenofovir 1% gelExploring the feasibility of multi-site flow cytometric processing of gut associated lymphoid tissue with centralized data analysis for multi-site clinical trialsAge, comorbidities, and AIDS predict a frailty phenotype in men who have sex with menInteractive Voice Response System: Data Considerations and Lessons Learned During a Rectal Microbicide Placebo Adherence Trial for Young Men Who Have Sex With MenAdherence to rectal gel use among mainly ethnic minority young men who have sex with men during a 3-month placebo gel trial: implications for microbicide research.Gastrointestinal mucosal biopsy in HIV disease and AIDS.A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate.Age-related prevalence of anal cancer precursors in homosexual men: the EXPLORE study.Order of orifices: sequence of condom use and ejaculation by orifice during anal intercourse among women: implications for HIV transmissionProtection of HIV neutralizing aptamers against rectal and vaginal nucleases: implications for RNA-based therapeutics.A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007).Risk factors for acquisition and clearance of oral human papillomavirus infection among HIV-infected and HIV-uninfected adults.A longitudinal study of human papillomavirus 16 L1, e6, and e7 seropositivity and oral human papillomavirus 16 infectionFactors affecting the prevalence of strongly and weakly carcinogenic and lower-risk human papillomaviruses in anal specimens in a cohort of men who have sex with men (MSM).Rectal-specific microbicide applicator: evaluation and comparison with a vaginal applicator used rectally.Association between free testosterone levels and anal human papillomavirus types 16/18 infections in a cohort of men who have sex with menA Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study).The slippery slope: lubricant use and rectal sexually transmitted infections: a newly identified risk.Risk factors for oral HPV infection among a high prevalence population of HIV-positive and at-risk HIV-negative adults.Use of nucleic acid amplification testing for diagnosis of anorectal sexually transmitted infectionsProject Gel a Randomized Rectal Microbicide Safety and Acceptability Study in Young Men and Transgender Women.The Molecular Characterization of Intestinal Explant HIV Infection Using Polymerase Chain Reaction-Based Techniques.Anal human papillomavirus infection is associated with HIV acquisition in men who have sex with men.Awareness of Post-Exposure Prophylaxis (PEP) and Pre-Exposure Prophylaxis (PrEP) Is Low but Interest Is High Among Men Engaging in Condomless Anal Sex With Men in Boston, Pittsburgh, and San Juan.High Oral Human Papillomavirus Type 16 Load Predicts Long-term Persistence in Individuals With or at Risk for HIV InfectionRMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarateInfluence of Partner Type on Acceptability and Likelihood of Use of a Rectal Microbicide Among Young Men Who Have Sex With Men in the United States and Puerto Rico.Acceptability of potential rectal microbicide delivery systems for HIV prevention: a randomized crossover trial.Anal Cancer Screening in Men Who Have Sex With Men in the Multicenter AIDS Cohort Study.Association of serum cytokines with oral HPV clearance.Anal human papillomavirus and HIV: A cross-sectional study among men who have sex with men in Moscow, Russia, 2012-2013To Use a Rectal Microbicide, First Insert the Applicator: Gel and Applicator Satisfaction Among Young Men Who Have Sex With Men.Anal human papillomavirus infection in a street-based sample of drug using HIV-positive men.A randomized male tolerance study of dapivirine gel following multiple topical penile exposures (MTN 012/IPM 010).Anal cytology screening in HIV-positive men who have sex with men: what's new and what's now?Incidence and epidemiology of anal cancer in the multicenter AIDS cohort studyControlled management of public relations following a public health incident.Age-Specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study.Progression of anal high-grade squamous intraepithelial lesions to invasive anal cancer among HIV-infected men who have sex with men.
P50
Q28544439-19B4EE32-4610-40B9-A665-1AC117F6C1E5Q28545969-D8041B8F-88A6-4959-B3CC-D53D5482035BQ30958546-9EE65587-F93D-4B8C-BC28-13276978D49EQ33684558-5D4A6E8D-5CAE-41CB-ACA6-50DFE12F9AABQ33830257-13C51F88-6457-4477-9CDB-A3E4C5C86F50Q34022053-6C723BD9-DDC2-4ADF-94CF-FB0E4EB0450AQ34063287-CA56475E-2F38-40B8-8AE1-55279C36DD9EQ34414539-AC44E528-7E3D-466B-9797-D47BA14EF392Q34426597-BD9D76E9-78BE-422F-B8E3-2F097DE33D53Q34440636-B3ADCD6B-C163-4CBD-9943-22A9466315F6Q34509294-8812C6DA-B634-479A-A680-EAC1E9B65571Q34661892-1B6E54D2-0AE8-4C2D-8F00-ECFCB3978234Q34882577-CB70252A-E652-4400-8D28-227B03FC3CB6Q34970731-E07E6999-5925-42E8-A7F8-C750A27374EAQ35053172-55301348-DCAB-4D0B-A3C5-D35FBD5C905EQ35061678-E728ED04-FA21-443D-A8FC-7F8938A2D776Q35203345-47BF5C50-4285-4A76-84C1-DE2F2C0F48AFQ35571216-34B5D93F-4825-4F3C-901F-621CDAEDC749Q35629984-6565DD91-50C2-4E09-9650-DB0F038644A4Q35758895-AC0CC7FD-E2E0-4731-BA86-F736F01487FDQ36022965-E6A1A4F4-91E8-4800-B7E1-654A7BCBCA50Q36065036-C874C259-B089-4601-88A3-63304C5AA2C3Q36078433-6BAAA63C-17C5-4C11-8B2A-37F71F3B5E90Q36079480-FFBFCD64-8D56-4545-91B8-EBC29135B174Q36175090-E3E4F1C7-995E-471F-9EC7-58ACCC9972C4Q36208618-6A0421A2-FD15-406A-A671-CBBEF89E24FCQ36359092-255F9FC8-415A-44E5-9B98-51D6715EF9FBQ36421478-0434C2F4-BF85-42EF-93BE-4C740735A497Q36674543-430C352C-5B0F-4EA0-B044-292A1E22CA8EQ36677914-B2051D8E-1E6A-4AFE-848C-C61730A6D54AQ36923830-C0269DD3-20F6-431D-9141-6DF6389D598BQ36927058-9F4461C4-F5A1-4075-96EA-D1738E06B3A0Q37088184-EA43FFC2-95CF-41BB-A424-81BD0B0F79DDQ37508024-82BF02FE-B5AD-4366-97C3-A6A5F734109AQ37543238-2C91090C-606C-4A5D-8021-C3CCC365A6C5Q37638081-2BF21B81-F536-455E-83E6-DC5CEF9BA417Q37710115-A4B25121-2AA3-4D54-B39F-83BCDF2284AAQ39520255-A2CD8F51-63CF-4585-B055-A2395E528EF9Q39700791-8A6F27E1-2C19-4582-8BC0-322435280A63Q40130321-571334B4-BBFE-488B-A248-894DF21E4E13
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ross D Cranston
@ast
Ross D Cranston
@en
Ross D Cranston
@es
Ross D Cranston
@nl
Ross D Cranston
@sl
type
label
Ross D Cranston
@ast
Ross D Cranston
@en
Ross D Cranston
@es
Ross D Cranston
@nl
Ross D Cranston
@sl
prefLabel
Ross D Cranston
@ast
Ross D Cranston
@en
Ross D Cranston
@es
Ross D Cranston
@nl
Ross D Cranston
@sl
P108
P106
P108
P21
P31
P496
0000-0002-2687-6217